704 related articles for article (PubMed ID: 9519950)
1. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Halsey NA; Coberly JS; Desormeaux J; Losikoff P; Atkinson J; Moulton LH; Contave M; Johnson M; Davis H; Geiter L; Johnson E; Huebner R; Boulos R; Chaisson RE
Lancet; 1998 Mar; 351(9105):786-92. PubMed ID: 9519950
[TBL] [Abstract][Full Text] [Related]
2. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
Mwinga A; Hosp M; Godfrey-Faussett P; Quigley M; Mwaba P; Mugala BN; Nyirenda O; Luo N; Pobee J; Elliott AM; McAdam KP; Porter JD
AIDS; 1998 Dec; 12(18):2447-57. PubMed ID: 9875583
[TBL] [Abstract][Full Text] [Related]
3. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
4. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Johnson JL; Okwera A; Hom DL; Mayanja H; Mutuluuza Kityo C; Nsubuga P; Nakibali JG; Loughlin AM; Yun H; Mugyenyi PN; Vernon A; Mugerwa RD; Ellner JJ; Whalen CC;
AIDS; 2001 Nov; 15(16):2137-47. PubMed ID: 11684933
[TBL] [Abstract][Full Text] [Related]
5. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Whalen CC; Johnson JL; Okwera A; Hom DL; Huebner R; Mugyenyi P; Mugerwa RD; Ellner JJ
N Engl J Med; 1997 Sep; 337(12):801-8. PubMed ID: 9295239
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Colebunders R; Florence E
Lancet; 1998 Jun; 351(9118):1813. PubMed ID: 9635977
[No Abstract] [Full Text] [Related]
8. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
9. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
10. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
11. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Shang N; Mosimaneotsile B; Motsamai OI; Bozeman L; Davis MK; Talbot EA; Moeti TL; Moffat HJ; Kilmarx PH; Castro KG; Wells CD
Lancet; 2011 May; 377(9777):1588-98. PubMed ID: 21492926
[TBL] [Abstract][Full Text] [Related]
12. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
[TBL] [Abstract][Full Text] [Related]
13. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.
Fitzgerald DW; Desvarieux M; Severe P; Joseph P; Johnson WD; Pape JW
Lancet; 2000 Oct; 356(9240):1470-4. PubMed ID: 11081529
[TBL] [Abstract][Full Text] [Related]
14. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
15. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
[TBL] [Abstract][Full Text] [Related]
16. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
[TBL] [Abstract][Full Text] [Related]
18. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
19. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults.
Lim HJ; Okwera A; Mayanja-Kizza H; Ellner JJ; Mugerwa RD; Whalen CC
HIV Clin Trials; 2006; 7(4):172-83. PubMed ID: 17065029
[TBL] [Abstract][Full Text] [Related]
20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
